TESARO, Inc. (TSRO) Given a $198.00 Price Target at Credit Suisse Group
TESARO, Inc. (NASDAQ:TSRO) has been assigned a $198.00 price target by Credit Suisse Group in a report issued on Wednesday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Credit Suisse Group’s price target would indicate a potential upside of 50.03% from the stock’s current price.
TSRO has been the topic of a number of other reports. Piper Jaffray Companies initiated coverage on shares of TESARO in a research note on Wednesday, April 12th. They issued an “overweight” rating and a $180.00 target price on the stock. Cowen and Company reiterated a “market perform” rating and issued a $145.00 target price on shares of TESARO in a research note on Tuesday, March 28th. Cann reiterated a “buy” rating and issued a $199.00 target price on shares of TESARO in a research note on Monday, June 5th. FBR & Co reiterated a “hold” rating on shares of TESARO in a research note on Monday, April 3rd. Finally, Citigroup Inc. reiterated a “buy” rating and issued a $216.00 target price (down from $232.00) on shares of TESARO in a research note on Saturday, April 22nd. Two analysts have rated the stock with a sell rating, nine have issued a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $173.74.
Shares of TESARO (NASDAQ:TSRO) traded up 2.29% during midday trading on Wednesday, reaching $131.97. 1,697,801 shares of the company traded hands. The firm’s market capitalization is $7.11 billion. TESARO has a 12-month low of $83.26 and a 12-month high of $192.94. The company has a 50-day moving average of $139.02 and a 200 day moving average of $151.61.
TESARO (NASDAQ:TSRO) last released its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($2.55) earnings per share for the quarter, missing the consensus estimate of ($2.26) by $0.29. TESARO had a negative return on equity of 96.49% and a negative net margin of 910.35%. The firm had revenue of $3.10 million for the quarter, compared to analysts’ expectations of $3.84 million. During the same quarter last year, the firm posted ($2.22) earnings per share. The firm’s revenue for the quarter was up 909.8% compared to the same quarter last year. On average, equities analysts forecast that TESARO will post ($8.66) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/07/23/tesaro-inc-tsro-given-a-198-00-price-target-at-credit-suisse-group.html.
In related news, VP Edward C. English sold 8,500 shares of the company’s stock in a transaction that occurred on Tuesday, June 6th. The shares were sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the sale, the vice president now owns 5,396 shares of the company’s stock, valued at approximately $748,155.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 40.50% of the company’s stock.
A number of hedge funds have recently bought and sold shares of the company. Whittier Trust Co. raised its stake in TESARO by 2.9% in the second quarter. Whittier Trust Co. now owns 11,506 shares of the biopharmaceutical company’s stock worth $1,609,000 after buying an additional 320 shares during the period. Aperio Group LLC raised its position in shares of TESARO by 4.5% in the second quarter. Aperio Group LLC now owns 3,658 shares of the biopharmaceutical company’s stock worth $512,000 after buying an additional 156 shares during the last quarter. Oregon Public Employees Retirement Fund bought a new position in shares of TESARO during the second quarter worth approximately $993,000. Mn Services Vermogensbeheer B.V. bought a new position in shares of TESARO during the second quarter worth approximately $855,000. Finally, Creative Planning raised its position in shares of TESARO by 2,328.6% in the second quarter. Creative Planning now owns 30,358 shares of the biopharmaceutical company’s stock worth $4,246,000 after buying an additional 29,108 shares during the last quarter.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.